Michael Shulman

Biotech Opportunities: Look for Decent Pipeline, Big Pharma Partnerships

You may have missed the common with the best partnership imaginable, very promising technology extensive to many cancer tumor types with several trials underway - Curis (CRIS). The partner is Genentech/Roche and the normally button downed biotech giant is so confident of Curis Hedgehog technology it has listed its first indication -- basal cell melanoma - as a 2011 launch based on a successful Phase II -- yes, Phase II - pivotal trial. Curis is also on the verge of licensing another molecule. For purposes of disclosure I own the stock.